-+ 0.00%
-+ 0.00%
-+ 0.00%
Minovar announced that the company recently received the European CEP certificate for venlafaxine hydrochloride API issued by the European Medicines Quality Administration. The company submitted a CEP application in December 2025. Up to now, the project has invested about 1,2512,000 yuan. Venlafaxine hydrochloride preparations are suitable for treating depression and generalized anxiety disorder. Currently, a total of 5 domestic companies have obtained CEP certificates for this API. In 2025, global sales of this API will be US$1,511 million, and national sales will be US$608.16,600.
Share
Listen to the news
Minovar announced that the company recently received the European CEP certificate for venlafaxine hydrochloride API issued by the European Medicines Quality Administration. The company submitted a CEP application in December 2025. Up to now, the project has invested about 1,2512,000 yuan. Venlafaxine hydrochloride preparations are suitable for treating depression and generalized anxiety disorder. Currently, a total of 5 domestic companies have obtained CEP certificates for this API. In 2025, global sales of this API will be US$1,511 million, and national sales will be US$608.16,600.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending